Pharma’s Digital Pathology Build-Out; Part 1 – The State Of Play

Pharma companies are applying digital pathology throughout their research and development functions. Where are they now finding value?  

Build out
Pharma is building digital pathology capacity • Source: Shutterstock

Large pharmaceutical companies are eager to talk about their digital transformation and their whole-hearted adoption of computational biology and artificial intelligence (AI). In the same vein, many are enthusiastically emphasizing the contributions digital pathology is making throughout their R&D organizations.

Digital pathology is helping pharma across the spectrum of drug discovery and development. (See Exhibit 1.) The technology digitizes hematoxylin...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.